El año pasado, Jazz Pharmaceuticals PLC generó 1.66B USD en su segmento con mejor rendimiento, Xywav. United States realizó la mayor aportación, representando 3.83B USD el año pasado. Para el último trimestre, Jazz Pharmaceuticals PLC reportó unos ingresos de 471.20M USD para el periodo finalizado el 2026-06-30, procedentes del segmento con mejor rendimiento, Xywav. United States aportó los mayores ingresos, alcanzando los 1.08B USD.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Xywav

Epidiolex/epidyolex

Rylaze

Zepzelca

High-sodium oxybate AG royalty revenue

Defitelio/defibrotide

Vyxeos

Xyrem

Modeyso

Royalties and contract revenues

Ziihera

sativex

Other Revenue

Oxybate

Sunosi

Erwianaze/Erwinase

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Xywav

1.66B(38.83%)

1.47B(36.21%)

1.27B(33.20%)

--(--)

Epidiolex/epidyolex

1.06B(24.82%)

972.42M(23.90%)

845.47M(22.05%)

--(--)

Rylaze

402.92M(9.44%)

410.85M(10.10%)

394.23M(10.28%)

281.66M(7.70%)

85.63M(2.77%)

--(--)

Zepzelca

307.31M(7.20%)

320.32M(7.87%)

289.53M(7.55%)

269.91M(7.38%)

246.81M(7.98%)

90.38M(3.82%)

--(--)

High-sodium oxybate AG royalty revenue

211.72M(4.96%)

217.57M(5.35%)

75.92M(1.98%)

--(--)

Defitelio/defibrotide

199.39M(4.67%)

216.56M(5.32%)

184.00M(4.80%)

194.29M(5.31%)

197.93M(6.40%)

195.84M(8.29%)

172.94M(8.00%)

Vyxeos

146.71M(3.44%)

162.59M(4.00%)

147.50M(3.85%)

127.98M(3.50%)

134.06M(4.33%)

121.11M(5.12%)

121.41M(5.62%)

Xyrem

146.03M(3.42%)

233.82M(5.75%)

569.73M(14.86%)

--(--)

Modeyso

48.04M(1.13%)

--(--)

Royalties and contract revenues

34.01M(0.80%)

30.21M(0.74%)

21.34M(0.56%)

17.95M(0.49%)

15.24M(0.49%)

16.91M(0.72%)

26.16M(1.21%)

Ziihera

24.81M(0.58%)

1.05M(0.03%)

--(--)

sativex

16.28M(0.38%)

18.88M(0.46%)

19.67M(0.51%)

--(--)

Other Revenue

14.17M(0.33%)

11.47M(0.28%)

13.85M(0.36%)

6.64M(0.18%)

9.80M(0.32%)

6.84M(0.29%)

17.55M(0.81%)

Oxybate

--(--)

1.98B(54.08%)

--(--)

1.76B(74.34%)

1.64B(75.98%)

Sunosi

--(--)

782.07M(21.37%)

2.34B(75.48%)

28.33M(1.20%)

3.71M(0.17%)

Erwianaze/Erwinase

--(--)

69.38M(2.24%)

147.14M(6.23%)

177.47M(8.21%)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

United States

Europe

All Others

All Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

3.83B(89.78%)

3.66B(89.95%)

3.49B(91.02%)

3.37B(92.10%)

2.82B(91.14%)

2.14B(89.08%)

1.97B(89.01%)

Europe

341.12M(7.99%)

312.71M(7.69%)

269.24M(7.02%)

239.64M(6.55%)

230.16M(7.44%)

175.21M(7.28%)

150.20M(6.80%)

All Others

94.87M(2.22%)

96.14M(2.36%)

74.98M(1.96%)

49.36M(1.35%)

43.84M(1.42%)

43.82M(1.82%)

46.24M(2.09%)

All Other

--(--)

43.82M(1.82%)

46.24M(2.09%)